期刊文献+

甲异靛对急性早幼粒细胞白血病细胞系NB_4体外作用的研究 被引量:5

Studying of effects of meisoindigo on acute promyelocytic leukemia cell line NB_4 cells in vitro
原文传递
导出
摘要 目的探讨甲异靛对NB4细胞系的抑制增生、诱导凋亡和分化的作用。方法用锥虫蓝染色方法进行活细胞计数;用NBT还原实验和CD11a、CD11b的表达判定促分化作用;光镜和电镜细胞形态学、TUNEL标记和Sub-G1测定观察细胞凋亡,RT-PCR和流式细胞术分析法检测凋亡调控基因mRNA及蛋白水平表达。结果20μmol/L和30μmol/L甲异靛可明显抑制NB4细胞的增生,诱导细胞凋亡并下调bcl-2表达,使细胞停滞在G0/G1期。5μmol/L和10μmol/L时NB4细胞的NBT还原能力明显升高,CD11a表达明显升高。结论甲异靛通过诱导细胞凋亡和使细胞停滞在G0/G1期这两种机制显著抑制NB4细胞增生,此外,还有部分诱导细胞分化的作用。 Objective To investigate the effects of meisoindigo on proliferation inhibit, induce apoptosis and differentiation of NB4 cells in vitro. Methods The cell growth rate was tested by trypan blue. The effects of induce differentiation were determined by detection of the NBT reduction value and the expression of CD11a. The effects of induce apoptosis were. determined by morphology, TUNEL labeling and detection of Sub- G1 cell population. The mRNA and protein expression levels of apoptosis regulation genes were detected by RT- PCR and FACS assay. Results 20 μmol/L and 30 μmol/L meisoindigo significantly inhibited the growth of NB4 cells, induced the NB4 cells to apoptosis, decreased the expression of bcl- 2 on mRNA and protein level, and arrested the cells in the G0/G1 phase in concentration- and time- dependent manner. 5 μmol/L and 10 μmol/L meisoindigo significantly increased the NBT reduction value and the expression of CD11a as compared with the control. Conclusions Meisoindigo significantly inhibited the proliferation of NB4 cells through inducing cell to apoptosis and arresting the cells in the G0/G1 phase of the cell cycle, and partially induced differentiation of NB4 cells. [
出处 《白血病.淋巴瘤》 CAS 2005年第3期136-139,共4页 Journal of Leukemia & Lymphoma
基金 人事部回国人员科研活动择优资助项目
关键词 甲异靛 NB4细胞系 增生 凋亡 分化 Meisoindigo NB4 cell line Proliferation Apoptosis Differentiation
  • 相关文献

参考文献8

  • 1Zhi jian Xiao, Linsheng Qian, Bingcheng Liu, et al.Meisoindigo for the treatment of chronic myelogenous leukemia[J]. Br J Haematol, 2000,111:711-712.
  • 2Zhijian Xiao, Yushu Hao, Bingcheng Liu, et al. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China[J]. Leuk Lymphoma,2002, 43:1763-1768.
  • 3王一,刘澎,刘兵城,彭智,钱林生,韩忠朝,肖志坚.甲异靛对慢性粒细胞白血病抗血管新生作用的体外研究[J].中华血液学杂志,2004,25(2):121-122. 被引量:16
  • 4Hoessel R, Leclerc S, Endicott J, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibit cycle-dependent kinases[Jl. Nature Cell Biol, 1999, 1:60- 67.
  • 5Liu X M, Wang L G, Li H Y, et al. Induction of differentiation and down - regulation of c - myb gene expression in ML - 1 human myeloblastic leukemia cells by the clinically effective anti- leukemia agent meisoindigo[J]. Biochem Pharmacol, 1996, 51 : 1545.
  • 6Raelson J V, Nervi C, Rosenauer A, et al. The PML/RAR α oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells[J]. Blood, 1996, 88:2826-2832.
  • 7Lazo G, Kantarjian H, Estey E, et al. Use of Arsenic Trioxide (As2O3)in the Treatment of Patients with Acute Promyelocytic Leukemia [J].Cancer, 2003, 97:2218-2224.
  • 8Rego E, He L, Warrell R, et al. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML- RARa and PLZF-RARa oncoproteins [J]. Proc Nail Acad Sci USA,2000,97: 10173-10178.

二级参考文献1

共引文献15

同被引文献48

  • 1吴英理,印彤,孙云,邬维礼,孙关林.甲异靛联合imatinib对CML K562细胞的促凋亡作用[J].上海第二医科大学学报,2005,25(5):433-436. 被引量:4
  • 2王一,朱孝峰,肖志坚,王鸿鹤,周军民,梅玉屏,邓蓉,姜文奇,刘宗潮.甲异靛诱导白血病细胞HL-60凋亡及机制探讨[J].癌症,2005,24(12):1464-1468. 被引量:6
  • 3Cooperative Study Group of Phase Ⅲ Clinical Trial on Meisoindico,Tianjin 300020.甲异靛治疗慢性粒细胞白血病 Ⅲ 期临床观察[J].中华血液学杂志,1997,18(2):69-72. 被引量:16
  • 4Xiao Z, Qian L, Liu B, et al. Meisoindigo for the treament of chronic myelogenous leukaemia. Br J Haematol, 2000, 111:711- 712.
  • 5Xiao Z, Hao Y, Liu B, et al. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma,2002,43 : 1763-1768.
  • 6Press RD,Love Z,Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood, 2006,107:4250-4256.
  • 7Ye D, Wolff N, Li L, et al. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood, 2006, 107:4917-4925.
  • 8Coppo P,Flamant S,De Mas V,et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol, 2006, 134 : 171-179.
  • 9de Groot RP,Raaijmakers JA, Lammers JW,et al. STATS activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood, 1999,94 : 1108-1112.
  • 10Xiao Z, Qian L,Liu B, et al. Meisoindigo for the treament of chronic myelogenous leukaemia. Br J Haematol,2000,111:711-712.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部